Q Therapeutics, Inc. has announced that it was awarded Patent Number 7,214,372, titled “Methods Using Lineage Restricted Glial Precursors from the Central Nervous System,” by the United States Patent and Trademark Office.
The patent contains claims to methods for increasing re-myelination of neurons in a human suffering from a disease or condition associated with demyelination of neurons and comprising administering to the human an effective amount of human glial restricted precursor cells partially differentiated into oligodendrocytes.
The patent also contains claims to methods for reducing glial scar formation in a human comprising administering to the human a composition comprising an effective amount of human glial restricted precursor cells partially differentiated into astrocytes. Q has exclusive worldwide license to this and other patents from the University of Utah, from the work of Dr. Mahendra Rao, a co-founder of Q.
“Q’s intellectual property estate around glial restricted progenitors, as well as other progenitor cells, is firmly established, and continues to expand,” said Deborah Eppstein, Ph.D., President and CEO of Q Therapeutics.
“With the issuance of this patent, Q now holds a portfolio of 15 patents and 23 pending patent applications in the field of neural progenitor cells in various jurisdictions worldwide.”